What is the first line bowel preparation laxative that is offered to patients undergoing colonoscopy?

Do you offer any alternative bowel preparation laxatives for patients undergoing colonoscopy?

How many patients received each bowel preparation laxative between 1st January 2018- 1^st January 2019?

What were the number of patients receiving each bowel preparation laxative who had inadequate bowel preparation between 1st January 2018- 1^st January 2019?

Are patients undergoing colonoscopy advised to take the bowel preparation at a single time or split over two different times?

During the period of 1st January 2018- 1^st January 2019, what times were patients advised to consume the bowel preparation for a morning colonoscopy appointment?

During the period of 1st January 2018- 1^st January 2019, what times were patients advised to consume the bowel preparation for an afternoon colonoscopy appointment?

During the period of 1st January 2018- 1^st January 2019, what times were patients advised to consume the bowel preparation for an evening colonoscopy appointment?

Are patient’s advised to consume a particular diet prior to their colonoscopy? If so what diet are they advised to consume? How many days are they advised to consume it for?

Do any of your patients attend a specific pre assessment clinic after they are referred for colonoscopy, but before they attend on the day of their endoscopy to receive more detailed endoscopy information? What is the criteria for referral to this pre assessment clinic?

How many patients are seen in this pre assessment clinic between 1st January 2018- 1^st January 2019?

How many colonoscopies did you perform in the last year (1st January 2018- 1^st January 2019)

During the period of 1st January 2018- 1^st January 2019:

• How many patients were documented as having excellent bowel preparation?
• What was the polyp detection rate in patient with excellent bowel preparation?
• How many patients were documented as having good bowel preparation?
• What was the polyp detection rate in patient with good bowel preparation?
• How many patients were documented as having fair bowel preparation?
• What was the polyp detection rate in patient with fair bowel preparation?
• How many patients were documented as having inadequate bowel preparation?
• What was the polyp detection rate in patient with inadequate bowel preparation?

How many patients had a morning appointment during the period of 1st January 2018- 1^st January 2019?

How many patients who had a morning appointment during the period of 1st January 2018- 1^st January2019 had inadequate bowel prep?

How many patients had an afternoon appointment during the period of 1st January 2018- 1^st January 2019?

How many patients who had an afternoon appointment during the period of 1st January 2018- 1^st January 2019 had inadequate bowel prep?

How many patients had an evening appointment during the period of 1st January 2018- 1^st January 2019?

How many patients who had an evening appointment during the period of 1st January 2018- 1^st January 2019 had inadequate bowel prep?

If a patient has a repeat colonoscopy due to inadequate bowel preparation, do you have a specific bowel preparation regime for those patients? If so what is it?

Please see attached documents

BOWEL PREPARATION INSTRUCTIONS

FOI 0384

QEColonoscopy

Freedom of Information Request: 0372 2019/20

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)? 22
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?

• Locally advanced 2
• Recurrent metastatic 0
• Unknown 0

3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

• Carboplatin (only or in combination with 5-FU) – 3
• Cisplatin (only or in combination with 5-FU) – 5
• Cetuximab with/without chemotherapy – 2
• Cetuximab with radiotherapy – 0
• Pembrolizumab monotherapy – 0
• Pembrolizumab with chemotherapy – 0
• Nivolumab –  4
• Docetaxel (only or in combination with 5-FU) – 0
• Fluorouracil (5FU) – 0
• Radiotherapy only – 9
• Other

4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

• Aflibercept – 0
• Bevacizumab – 0
• Capecitabine – 14
• CAPIRI – 0
• CAPOX – 32
• Cetuximab not in combination with FOLFIRI or FOLFOX – 0
• Cetuximab in combination with FOLFIRI – 13
• Cetuximab in combination with FOLFOX – 3
• Irinotecan – 5
• FOLFIRI – 32
• FOLFOX – 33
• Oxaliplatin – 3
• Panitumumab not in combination with FOLFIRI or FOLFOX – 0
• Panitumumab in combination with FOLFIRI – 1
• Panitumumab in combination with FOLFOX – 0
• Nivolumab – 2
• Raltitrexed – 2
• Ramucirumab – 0
• Regorafenib – 0
• Sorafenib – 0
• 5FU only – 91
• Tegafur Uracil + 5FU – 0
• Trifluridine–tipiracil – 0
• XELOX – 31
• Other – 55

Freedom of Information Request: 0365 2019/20

• In the last six months how many patients in your trust have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently having treatment? 1,655

• Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS?

• How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the last 6 months. If you could, please include all patients whose treatment is ongoing,  even those with infrequent dosing schedules (e.g. patients treated with Lemtrada, Mavenclad, Ocrevus)

• Could you please provide the total number of patients being treated with the following drugs:

Please see attached document

FOI 0365

Freedom of Information Request: 0342 2019/20

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the following conditions.

Please see attached document

FOI 0342

Freedom of Information Request: 0418 2019/20

1. Do you have an internal or external RPI/Security team? Security staff employed by the Trust are all external bought in under contract.
2. Do these staff wear stab vests? All security staff on all sites wear stab vests
3. Do they use/wear body worn cameras/video? Only security at QE use body worn cameras
4. If Internal employees, what pay band are the roles? Not Applicable

Freedom of Information Request: 0410 2019/20

We understand from your Trust’s guideline CG009 ‘Thrombolysis and Thrombectomy’

version 3.1 that at the time of the policy there was an out of hours thrombectomy service provided on a case-by-case basis and the expectation a full 24 hour thrombectomy service would be in place in 2017.

Please would you provide the following information:

1. The date the 24 hour thrombectomy service was established at the Queen Elizabeth Hospital Birmingham.

The 24 hour thrombectomy service was due to start in September 2019.  Due to workforce issues we have explanded the service from this date to a 7am to 7pm service, 7 days a week but still not 24/7.

2. If the thrombectomy service was not a 24 hour service in December 2018, the ‘usual’ hours the service did operate at that time.

Still 9am to 5pm Monday to Friday in December 2018

3. If the thrombectomy service was not a 24 hour service in December 2018, the system in place for “case-by-case basis” thrombectomy to be performed out-of-hours (as referred to in the CG009 policy). We require information regarding the working of this process, including what times were classified as ‘out of hours’; the arrangements for an on-call neuroradiologist, anaesthetist and theatre team; the criteria applied to judge cases on a “case-by-case” basis; and timeframes.

Out of hours is anytime outside the times outlined above.  There was no on-call neuroradiologist or neuoraneaesthetist at this time, the on-call angio staff were not present 24 hours a day because most other neuro-interventions can wait several hours.  If there was a clear thrombectomy case the stroke physician would see if an available team could be mobilised and consider if the team and room could be ready in sufficient time to make a thrombectomy viable in that particular case.

4. Please provide a copy of the subsequent version of your CG009 ‘Thrombolysis and

Thrombectomy’ guideline. We note the review date of version 3.1 we hold was

November 2018.

Please see attached document

CG009 Stroke Thrombolysis Thrombectomy – Guidelines

Freedom of Information Request: 0405 2019/20

1. Has the pharmacy of your hospital(s) dispensed Ursodeoxycholic Acid 250mg capsules between the following periods?:

• from September 1, 2017 till August 31, 2018

• from September 1, 2018 till August 31, 2019

2. If the answer is ‘yes’ to request 1, could you please send me details in below requested format:

Freedom of Information Request: 0396 2019/20

Under the Freedom of information Act 2000, please will you provide the following details relating to ground maintenance and gardening service contracts given out or awarded by the NHS (West Midlands):

1. What was the annual budget for contract ground maintenance and gardening services undertaken at each of the following hospitals sites for the years 2017/2018?

1. Solihull hospital
2. Birmingham Heartlands hospital
3. Good Hope hospital

2. How much is budgeted to be spent on contract ground maintenance and gardening services at each of the following hospitals sites in 2019/2020 and 2020/2021?

1. Solihull hospital
2. Birmingham Heartlands hospital
3. Good Hope hospital

3. How much was actually spent on contract ground maintenance and garden services at each of the following hospital sites in 2017/2018 and 2018/2019

1. Solihull hospital
2. Birmingham Heartlands hospital
3. Good Hope hospital

4. Which department, service or company is currently contracted (or has responsibility) for providing ground maintenance and gardening services at each of the following hospital sites?

1. Solihull hospital
2. Birmingham Heartlands hospital
3. Good Hope hospital

Finally can you provide the details of the main contact (person, department, service or company) who awards and (or) arranges/manages the NHS hospital ground maintenance and gardening service contracts in the West Midlands

Please see attached document

FOI 0396

Freedom of Information Request: 0394 2019/20

I would like to request the following information with regards to the organisation’s telephone system maintenance contract (VOIP or PBX, other) for hardware and software maintenance and support.

• What manufacturer (hardware) telephone system are you using? e.g. Avaya, BT, Cisco etc. 

QE: Cisco

HGS: Realtis DX moving to Cisco by Jan 2020

• Approximately how many extensions does the system support?

HGS: Approximately 500

QEHB: Approximately 7000

• Who’s the incumbent/support partner for the maintenance of your PBX?

HGS: Maintel UK

QEHB: Kcom

• How many of those extensions would you say are contact centre/customer service agents? Not Valid Under Freedom of Information

• And finally, when does support contract expire? UHB: January 2020

Freedom of Information Request: 0392 2019/20

1. What is the size of your informatics team (FTE)?

2. What percentage of time is spent on workforce/employee reporting (as compared with clinical reporting etc.)

2a. of the workforce/employee reporting, what is the estimated time split between standard and non-standard (custom) reporting. (examples of standard reports could include the weekly and monthly agency returns to NHS improvement and HR reporting inputs to the monthly board reports)

3. Does the trust use an analytics platform or a business intelligence (BI) reporting tool to support your reporting requirements? If so, can you please answer the below:

a. Name of the platform/reporting tool used (i.e, Qlik, Tableau, Spotfire, Microsoft)

b. Annual cost for 18/19:

c. Contract start and end date:

Please see attached document

FOI 0392